FDA approves Pfizer's rheumatoid arthritis treatment

Share this article:
FDA approves Pfizer's rheumatoid arthritis treatment
FDA approves Pfizer's rheumatoid arthritis treatment
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually. Xeljanz is taken in 5-milligram pills twice daily.  About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wound healing.
Share this article:

More in Products

FDA approves weight management drug

The U.S. Food and Drug Administration has approved Contrave as a treatment for chronic weight management. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation.

PDI introduces new swab

PDI introduces new swab

PDI has debuted the PrevanticsĀ® Device Swab, a chlorhexidine gluconate/alcohol solution that has received market authorization from the U.S. Food and Drug Administration for disinfecting needleless access sites prior to ...

Oregon Freeze Dry releases Easy Meal

Oregon Freeze Dry releases Easy Meal

A new brand from Oregon Freeze Dry is designed to help long-term care and other healthcare facilities prepare for a disaster.